The Food and Drugs Authority (FDA) has suspended the production of Tasty Tom Enriched Tomato Mix by Nutrifoods Ghana Limited following a probe that revealed serious quality control failures at the company’s manufacturing facility. The decision comes after several consumer complaints and an FDA investigation that confirmed contamination in certain batches, posing health risks to the public.
In a public notice issued on August 1, 2025, Nutrifoods Ghana announced a voluntary recall of all affected batches of Tasty Tom Enriched Tomato Mix in 210g and 400g canned formats, as well as 380g and 1.05kg pouch variants. The company listed 12 specific batch numbers for the recall, with expiry dates ranging from January 20 to January 24, 2027.
The investigation revealed issues such as faulty sealing, poor maintenance of critical equipment, and inadequate monitoring systems, which led to bloating and mold growth in some products.
Nutrifoods confirmed in the release that the FDA had suspended their canning lines in January 2025, halting production of the 210g and 400g canned products. Additionally, they stated that all manufacturing operations have now been suspended until further notice to comply with regulatory requirements.
“We are working closely with the FDA to ensure that this recall process goes as smoothly as possible,” Nutrifoods said. “We deeply regret any inconvenience caused to our consumers and trade partners because of this issue and recall.”
Consumers who possess affected products are urged not to consume them. Instead, they should return them to Nutrifoods’ Tema office or any authorized distributor nationwide. For inquiries, the public can contact 050 5384429 (Monday to Friday, 8:00am to 8:00pm) or email [email protected].
Nutrifoods reiterated its commitment to high food safety standards and assured the public that it is doing everything possible to recover and replace the affected products.
“We want to reassure our consumers and trade partners that we are doing our best to recover all affected products and replace them without difficulty,” the company stated.
The FDA has also begun an internal review to determine whether any regulatory lapses allowed unauthorized production to resume after the earlier suspension.
